Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Preliminary Data on Vaccine Protection against Omicron Using a test-negative study design focused on the period of dominance of the B.1.1.529 (omicron) variant in South Africa, investigators found that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by omicron in Gauteng province.

Automated summary

Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.